Table 2

Estimated ORs and 95% CIs from multivariate models of diabetes care and outcomes

HbA1c >9%†‡§No HbA1c laboratory test in 2011LDL≥100†No LDL laboratory test in 2011SBP≥130†No SBP reading in 2011Diabetes drug adherence ≥80%¶‡
American Indian/Alaska Native (reference: non-Hispanic Caucasian)1.41*** (1.31 to 1.51)0.96 (0.90 to 1.03)1.03 (0.99 to 1.08)1.01 (0.94 to 1.08)1.03 (0.99 to 1.06)0.92 (0.83 to 1.02)0.90*** (0.88 to 0.93)
  • All models control for patient age and gender, geocoded Census Block Group income and education, HMO site, duration of diabetes, and comorbidities using the Quan Modified Elixhauser Comorbidity Scale.

  • *Statistically significant at p<0.05, **p<0.01, ***p<0.001.

  • †Restricted to patients with a measurement in year 2011.

  • ‡Model controls for whether patient had a dispensing of insulin in year 2011.

  • §Model controls for whether patient had a dispensing of an oral diabetes medication in year 2011.

  • ¶Restricted to patients with drug coverage who had two or more dispensings of an oral diabetes medication in the same drug class in year 2011.

  • LDL, low-density lipoprotein; HbA1c, glycated haemoglobin; SBP, systolic blood pressure.